WHO suspends hydroxychloroquine trial as COVID-19 treatment
The World Health Organization said Monday it had temporarily suspended clinical trials of hydroxychloriquine as a potential treatment for COVID-19 being carried out across a range of countries as a precautionary measure.
The decision came after publication last week of a study in The Lancet which indicated that using the drug on COVID-19 patients could increase their chances of dying, WHO chief Tedros Adhanom Ghebreyesus told a virtual press conference.
Tedros said that the executive group of the so-called Solidarity Trial, in which hundreds of hospitals across several countries have enrolled patients to test several possible treatments for the novel coronavirus, had as a precaution suspended trials using that drug.
“The Executive Group has implemented a temporary pause of the hydroxychloroquine arm within the Solidarity Trial while the safety data is reviewed by the Data Safety Monitoring Board,” Tedros said.
“The other arms of the trial are continuing,” he stressed.
Hydroxychloroquine is normally used to treat arthritis but pronouncement from public figures including US President Donald Trump—who announced last week he is taking the drug—has prompted governments to bulk buy the medicine.